Testing The Effect Of Adding Abiraterone Acetate And Enzalutamide To Metastatic Hormone Refractory Prostate Cancer, When Compared To Enzalutamide Alone
Posted Date: Aug 17, 2017
- Investigator: Nilesh Patil
- Specialties: Hematology/Oncology, Oncology, Cancer
- Type of Study: Drug
The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone and enzalutamide with enzalutamide alone on patients and their cancer to find out which is better. Doctors are uncertain about which way is the best way to treat castration resistant prostate cancer (CRPC). In previous studies, enzalutamide appeared to e at least as active as abiraterone in patients with CRPC who have received prior chemotherapy and it may be at least as active in patients who have not received chemotherapy.
To Be Eligible To Participate, Patients Must Have Prostate Cancer That Has Spread And Has Not Responded To Hormonal Therapy.
Abiraterone, Metastatic Prostate Cancer, Enzalutamide, Cancer, A031201
For More Information:
Uc Cancer Institute